Literature DB >> 11160019

Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus.

J Moss1, M E Ehrmantraut, B D Banwart, D W Frank, J T Barbieri.   

Abstract

Expression of type III proteins of Pseudomonas aeruginosa in patients with cystic fibrosis (CF) was investigated by measuring the immune response against components of the type III pathway. Twenty-three of the 33 sera contained antibodies against PcrV, a protein involved in translocation of type III cytotoxins into eukaryotic cells, and 11 of 33 had antibodies against ExoS, while most CF sera contained antibodies against PopB and PopD, components of the type III apparatus. These data indicate that P. aeruginosa commonly expresses components of the type III translocation apparatus in adult CF patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160019      PMCID: PMC98003          DOI: 10.1128/IAI.69.2.1185-1188.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Pseudomonas aeruginosa exoenzyme S disrupts Ras-mediated signal transduction by inhibiting guanine nucleotide exchange factor-catalyzed nucleotide exchange.

Authors:  A K Ganesan; T S Vincent; J C Olson; J T Barbieri
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

Review 2.  Phospholipase C: molecular biology and contribution to the pathogenesis of Pseudomonas aeruginosa.

Authors:  M L Vasil; L M Graham; R M Ostroff; V D Shortridge; A I Vasil
Journal:  Antibiot Chemother (1971)       Date:  1991

3.  Purification and characterization of exoenzyme S from Pseudomonas aeruginosa 388.

Authors:  S M Kulich; D W Frank; J T Barbieri
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

4.  Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay.

Authors:  J D Klinger; D C Straus; C B Hilton; J A Bass
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

5.  IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  S M Cordon; J S Elborn; R J Rayner; E J Hiller; D J Shale
Journal:  Arch Dis Child       Date:  1992-06       Impact factor: 3.791

6.  Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils.

Authors:  D Dacheux; B Toussaint; M Richard; G Brochier; J Croize; I Attree
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

7.  Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening.

Authors:  S H Abman; J W Ogle; R J Harbeck; N Butler-Simon; K B Hammond; F J Accurso
Journal:  J Pediatr       Date:  1991-08       Impact factor: 4.406

8.  Immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients with cystic fibrosis or bacteremia.

Authors:  A Brauner; S J Cryz; M Granström; H S Hanson; L Löfstrand; B Strandvik; B Wretlind
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

9.  Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients.

Authors:  G Kronborg; A Fomsgaard; C Galanos; M A Freudenberg; N Høiby
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

10.  IgG subclass antibody responses to alginate from Pseudomonas aeruginosa in patients with cystic fibrosis and chronic P. aeruginosa infection.

Authors:  T Pressler; S S Pedersen; F Espersen; N Høiby; C Koch
Journal:  Pediatr Pulmonol       Date:  1992-09
View more
  21 in total

1.  Examination of the coordinate effects of Pseudomonas aeruginosa ExoS on Rac1.

Authors:  Claudia L Rocha; Elizabeth A Rucks; Deanne M Vincent; Joan C Olson
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa.

Authors:  Arne Rietsch; Isabelle Vallet-Gely; Simon L Dove; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection.

Authors:  Vincent T Lee; Roger S Smith; Burkhard Tümmler; Stephen Lory
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

5.  Metabolic regulation of type III secretion gene expression in Pseudomonas aeruginosa.

Authors:  Arne Rietsch; John J Mekalanos
Journal:  Mol Microbiol       Date:  2006-02       Impact factor: 3.501

6.  Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis.

Authors:  Manu Jain; Daniel Ramirez; Roopa Seshadri; Joanne F Cullina; Catherine A Powers; Grant S Schulert; Maskit Bar-Meir; Christine L Sullivan; Susanna A McColley; Alan R Hauser
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

7.  The Pseudomonas aeruginosa PA01 gene collection.

Authors:  Joshua Labaer; Qingqing Qiu; Anukanth Anumanthan; Wenhong Mar; Dongmei Zuo; T V S Murthy; Helen Taycher; Allison Halleck; Eugenie Hainsworth; Stephen Lory; Leonardo Brizuela
Journal:  Genome Res       Date:  2004-10       Impact factor: 9.043

8.  Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.

Authors:  Joshua T Thaden; Ashley E Keller; Norah J Shire; M Margarita Camara; Linda Otterson; Mike Huband; Caitlin M Guenther; Wei Zhao; Paul Warrener; C Kendall Stover; Vance G Fowler; Antonio DiGiandomenico
Journal:  J Infect Dis       Date:  2015-09-02       Impact factor: 5.226

Review 9.  Pseudomonas aeruginosa virulence and therapy: evolving translational strategies.

Authors:  Jeffrey L Veesenmeyer; Alan R Hauser; Thiago Lisboa; Jordi Rello
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

Review 10.  The type III secretion system of Pseudomonas aeruginosa: infection by injection.

Authors:  Alan R Hauser
Journal:  Nat Rev Microbiol       Date:  2009-09       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.